P2RX7 and multiple sclerosis: As such, from a drug discovery perspective, P2X7 is an ideal drug target as antagonism of a silent channel by true neutral antagonists would not cause any serious target mediated (adverse) effects, i.e., antagonism will only elicit when the channel is activated by high ATP concentrations (i.e., on-demand activation, danger signal), which is believed to be achieved during pathology of neuroinflammatory disorders of the CNS such as stroke, epilepsy, multiple sclerosis, chronic neurodegenerative, and neuropsychiatric diseases.